相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease
Alan Whone et al.
BRAIN (2019)
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease
Alan L. Whone et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease
C. Warren Olanow et al.
BRAIN (2019)
Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease
John D. Heiss et al.
MOVEMENT DISORDERS (2019)
Do subjects with minimal motor features have prodromal Parkinson disease?
Yaping Chu et al.
ANNALS OF NEUROLOGY (2018)
Structure and biophysical characterization of the human full-length neurturin-GFRa2 complex: A role for heparan sulfate in signaling
Jenny Sandmark et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway
Rekha Raghunathan et al.
MOLECULAR & CELLULAR PROTEOMICS (2018)
Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel?
Ava Nasrolahi et al.
REVIEWS IN THE NEUROSCIENCES (2018)
Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
Matthew J. Benskey et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?
Raymond T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2017)
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Nicholas M. Kanaan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2017)
Impact of age and vector construct on striatal and nigral transgene expression
Nicole K. Polinski et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
C. Warren Olanow et al.
ANNALS OF NEUROLOGY (2015)
Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression
Nikolaos Volakakis et al.
JOURNAL OF NEUROSCIENCE (2015)
Trophic Factors for Parkinson's Disease: To Live or Let Die
C. Warren Olanow et al.
MOVEMENT DISORDERS (2015)
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
R. T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2015)
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease
Jeffrey H. Kordower et al.
BRAIN (2013)
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
Christopher D. Herzog et al.
NEUROBIOLOGY OF DISEASE (2013)
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus et al.
NEUROLOGY (2013)
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease
Yaping Chu et al.
BRAIN (2012)
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease
Mickael Decressac et al.
BRAIN (2011)
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin
Maxim M. Bespalov et al.
JOURNAL OF CELL BIOLOGY (2011)
Novel mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung's disease
Macarena Ruiz-Ferrer et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
Raymond T. Bartus et al.
MOVEMENT DISORDERS (2011)
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease
Raymond T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2011)
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases
Christopher D. Herzog et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2011)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Striatal Readministration of rAAV Vectors Reveals an Immune Response Against AAV2 Capsids That Can Be Circumvented
Carmen S. Peden et al.
MOLECULAR THERAPY (2009)
Neurturin-mediated ret activation is required for retinal function
Milam A. Brantley et al.
JOURNAL OF NEUROSCIENCE (2008)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
Mehdi Gasmi et al.
NEUROBIOLOGY OF DISEASE (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Yaping Chu et al.
NEUROBIOLOGY OF DISEASE (2007)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered (vol 103, pg 12993, 2006)
Maria P. Limberis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered
Maria P. Limberis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Nurr1 in Parkinson's disease and related disorders
YP Chu et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2006)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach
C Schmitz et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2000)
分享论文
